Disseminated tuberculosis in 2 children with inflammatory bowel disease receiving infliximab.
Patients with inflammatory bowel disease are predisposed to opportunistic infections. We report 2 cases of disseminated tuberculosis in adolescents receiving a TNF antagonist, infliximab. Both had negative baseline tuberculin skin tests. Multimodal testing using tuberculin skin tests and interferon gamma release assays at the time of inflammatory bowel disease diagnosis and annually may increase the sensitivity of LTBI testing in these high risk children.
From the *Sections of Infectious Diseases; †Emergency Medicine; and †Gastroenterology and Nutrition, Department of Pediatrics; and §Department of Pediatric Radiology, Baylor College of Medicine, Houston, TX.
Andrea T
AT
Cruz
Lina B
LB
Karam
Robert C
RC
Orth
Jeffrey R
JR
Starke
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications* / Q000188:drug therapy*; D000069285:Infliximab; D059425:Interferon-gamma Release Tests; D055985:Latent Tuberculosis / Q000150:complications*; D008297:Male; D014374:Tuberculin Test; D014391:Tuberculosis, Miliary / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology
D000911:Antibodies, Monoclonal; D000069285:Infliximab